Research progress of diabetic retinopathy with dyslipidemia
10.3760/cma.j.issn.2095-0160.2017.07.017
- VernacularTitle:伴脂代谢紊乱的糖尿病视网膜病变研究进展
- Author:
Mengya, ZHAO
- Keywords:
Diabetic retinopathy;
Dyslipidemia;
Lipid-lowering therapy
- From:
Chinese Journal of Experimental Ophthalmology
2017;35(7):655-659
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy (DR) is one of the major microvascular complications of diabetes,it is the most common cause of preventable blindness in diabetic adults in developed countries.Dyslipidemia,a systemic disease,is one of the most important risk factors for cardiovascular disease.Patients with diabetes are susceptibly suffering from dyslipidemia.Many studies have shown that dyslipidemia can accelerate the progression of DR and aggravate the condition of DR,making the treatment of DR more difficult.The study on the mechanism of dyslipidemia aggravating DR provides a new way to treat and prevent DR by improving dyslipidemia.Current researches have shown that dyslipidemia may accelerate the progression of DR by exacerbating mitochondrial damage,insulin resistance,inflammatory response,and PKC/AGE pathway.Studies on lipid-lowering drugs,such as statins and fibrates and other lipid-lowering measures have shown that lipid-lowering is positive in the treatment of DR.This review summarizes the research progress of DR with dyslipidemia from the clinical features,potential mechanism and the effect of lipidlowering measures on DR.
